Full metadata record

DC FieldValueLanguage
dc.contributor.author이종민-
dc.date.accessioned2017-10-23T02:16:48Z-
dc.date.available2017-10-23T02:16:48Z-
dc.date.issued2015-12-
dc.identifier.citationAlzheimer's and Dementia, v. 2, Page. 58-67en_US
dc.identifier.issn2352-8729-
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S2352872915000937?via%3Dihub-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/30184-
dc.description.abstractIntroduction: Recent studies have shown that pathologically defined subtypes of Alzheimer's disease (AD) represent distinctive atrophy patterns and clinical characteristics. We investigated whether a cortical thickness-based clustering method can reflect such findings. Methods: A total of 77 AD subjects from the Alzheimer's Disease Neuroimaging Initiative 2 data set who underwent 3-T magnetic resonance imaging, [18F]-fluorodeoxyglucose-positron emission tomography (PET), [18F]-Florbetapir PET, and cerebrospinal fluid (CSF) tests were enrolled. After clustering based on cortical thickness, diverse imaging and biofluid biomarkers were compared between these groups. Results: Three cortical thinning patterns were noted: medial temporal (MT; 19.5%), diffuse (55.8%), and parietal dominant (P; 24.7%) atrophy subtypes. The P subtype was the youngest and represented more glucose hypometabolism in the parietal and occipital cortices and marked amyloid-beta accumulation in most brain regions. The MT subtype revealed more glucose hypometabolism in the left hippocampus and bilateral frontal cortices and less performance in memory tests. CSF test results did not differ between the groups. Discussion: Cortical thickness patterns can reflect pathophysiological and clinical changes in AD. © 2016 The Authors.en_US
dc.description.sponsorshipData collection and sharing for this project was funded by the Alzheimer''s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer''s Association; Alzheimer''s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICOLtd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer''s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013R1A1A1012925), grants of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C3319, A120798), a grant from Ministry of Trade, Industry and Energy (MOTIE; grant number: 10060305), a grant from the Korea Institute of Science and Technology Institutional Open Research Program (2E24242-13-110), and grants (2015-590; 2014-0783) from the Asan Institute for Life Sciences (J.H.R.).en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectAlzheimer's diseaseen_US
dc.subjectAlzheimer's Disease Neuroimaging Initiativeen_US
dc.subjectCortical thicknessen_US
dc.subjectMagnetic resonance imagingen_US
dc.subjectPositron emission tomographyen_US
dc.titlePrediction of Alzheimer's disease pathophysiology based on cortical thickness patternsen_US
dc.typeArticleen_US
dc.relation.volume2-
dc.identifier.doi10.1016/j.dadm.2015.11.008-
dc.relation.page58-67-
dc.relation.journalAlzheimer's and Dementia-
dc.contributor.googleauthorHwang, Jihye-
dc.contributor.googleauthorKim, Chan Mi-
dc.contributor.googleauthorJeon, Seun-
dc.contributor.googleauthorLee, Jong Min-
dc.contributor.googleauthorHong, Yun Jeong-
dc.contributor.googleauthorRoh, Jee Hoon-
dc.contributor.googleauthorLee, Jae-Hong-
dc.contributor.googleauthorKoh, Jae-Young-
dc.contributor.googleauthorNa, Duk L.-
dc.contributor.googleauthorAlzheimer's Disease Neuroimaging Initiative-
dc.relation.code2015018207-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDIVISION OF ELECTRICAL AND BIOMEDICAL ENGINEERING-
dc.identifier.pidljm-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > ELECTRICAL AND BIOMEDICAL ENGINEERING(전기·생체공학부) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE